For information 410.787.4000
Allfen ; Humibid® LA(reformulation)(reformulation)
Potassium Guaiacolsulfonate and Guaifenesin
Temporary control of cough associated with respiratory tract infections and related conditions which are complicated by tenacious mucus and/or mucus plugs and congestion
Reproduction studies have not been conducted.
Excretion in breast milk unknown/not recommended
Hypersensitivity to guaifenesin, potassium guaiacolsulfonate, or any component of the formulation
Underlying cause of cough should be determined prior to prescribing. Safety and efficacy have not been established in children <6 years of age.
Frequency not defined.
Central nervous system: Dizziness, headache
Dermatologic: Rash, urticaria
Endocrine & metabolic: Uric acid levels decreased
Gastrointestinal: Gastrointestinal discomfort, nausea, vomiting
Postmarketing and/or case reports: Kidney stone formation (with consumption of large quantities of guaifenesin)
Store at room temperature of 20°C to 25°C (68°F to 77°F), in a dry location.
Guaifenesin and potassium guaiacolsulfonate are both expectorants. Guaifenesin is thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing mucus viscosity.
Absorption: Guaifenesin: Well absorbed
Half-life elimination: Guaifenesin: ~1 hour
Excretion: Guaifenesin: Urine (as unchanged drug and metabolites)
Oral: Relief of cough:
Children 6-12 years (Allfen): One-half tablet every 12 hours; maximum 1 tablet/24 hours
Extended release tablets should not be crushed or chewed.
Possible interference with determination of 5-HIAA and VMA; discontinue for 48 hours prior to test.
No significant effects or complications reported
No information available to require special precautions
May cause dizziness or drowsiness
Tablet, sustained release:
Allfen: Guaifenesin 1000 mg and potassium guaiacolsulfonate 150 mg
Humibid® LA: Guaifenesin 600 mg and potassium guaiacolsulfonate 300 mg